<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1807">
  <stage>Registered</stage>
  <submitdate>18/01/2008</submitdate>
  <approvaldate>18/01/2008</approvaldate>
  <nctid>NCT00605111</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes</studytitle>
    <scientifictitle>Efficacy and Safety of Initiation of Biphasic Insulin Aspart 30 Treatment in Subjects With Type 2 Diabetes Mellitus Failing OAD Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BIASP-3021</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - biphasic insulin aspart

Treatment: drugs: biphasic insulin aspart


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>HbA1c</outcome>
      <timepoint>after 11 weeks of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of subjects achieving treatment target of HbA1c below 7%</outcome>
      <timepoint>at 11 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>8-point plasma glucose profiles</outcome>
      <timepoint>performed at 11 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FPG</outcome>
      <timepoint>at 11 weeks and 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type 2 diabetes for at least 24 months

          -  BMI between 18 and 30 kg/m2

          -  Insulin naive subjects

          -  OAD treatment with max two OADs alone or combined with other therapy

          -  HbA1c between 7-12%</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Type 1 diabetes

          -  Receipt of any investigational drug within the last three months prior to this trial

          -  Current or previous treatment with thiazolidiones within the last 6 months

          -  OAD treatment with three or more OADs within the last 4 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>193</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2004</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Novo Nordisk Investigational Site - Blacktown</hospital>
    <hospital>Novo Nordisk Investigational Site - Broadmeadow</hospital>
    <hospital>Novo Nordisk Investigational Site - Fitzroy</hospital>
    <hospital>Novo Nordisk Investigational Site - Garran</hospital>
    <hospital>Novo Nordisk Investigational Site - Stones Corner</hospital>
    <postcode>2148 - Blacktown</postcode>
    <postcode>2292 - Broadmeadow</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>2605 - Garran</postcode>
    <postcode>4120 - Stones Corner</postcode>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Shatin, New Territories</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Cheras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Georgetown, Penang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kota Bharu, Kelantan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Cebu City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Quezon City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaoshiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and
      safety of biphasic insulin aspart 30 as start insulin in subjects with type 2 diabetes
      failing OAD therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00605111</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>